Experienced in Alveolar Soft Part Sarcoma

Dr. John B. Fiveash

Neurosurgery | Radiation Oncology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Alveolar Soft Part Sarcoma
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Fiveash is a Neurosurgery specialist and a Radiation Oncologist in Birmingham, Alabama. Dr. Fiveash is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Brain Tumor, Metastatic Brain Tumor, Astrocytoma, Glioblastoma, and Gamma Knife Radiosurgery. Dr. Fiveash is currently accepting new patients.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Radiation Oncology
Licenses
Radiology in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus
RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
HyperArc Registry Study
HyperArc Registry Study
Enrollment Status: Completed
Publish Date: September 24, 2025
Intervention Type: Radiation
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer
RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer
Enrollment Status: Completed
Publish Date: January 12, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 10 Less Clinical Trials

114 Total Publications

Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS study.
Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS study.
Journal: International journal of radiation oncology, biology, physics
Published: July 18, 2025
Similar Doctors
Advanced in Alveolar Soft Part Sarcoma
Dr. Michael C. Dobelbower
Radiation Oncology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Michael C. Dobelbower
Radiation Oncology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Dobelbower is a Radiation Oncologist and an Oncologist in Birmingham, Alabama. Dr. Dobelbower is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Meningioma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Dobelbower is currently accepting new patients.

Experienced in Alveolar Soft Part Sarcoma
Dr. Kimberly S. Keene
Radiation Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Kimberly S. Keene
Radiation Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 miles away)
205-934-3460
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kimberly Keene is a Radiation Oncologist in Birmingham, Alabama. Dr. Keene is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Familial Prostate Cancer, and Prostate Cancer. Dr. Keene is currently accepting new patients.

Experienced in Alveolar Soft Part Sarcoma
Dr. Omer L. Burnett
Radiation Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Omer L. Burnett
Radiation Oncology

Alabama Cancer Care, LLC

291 James Payton Blvd, 
Sylacauga, AL 
 (37.4 miles away)
256-245-0297
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Omer Burnett is a Radiation Oncologist in Sylacauga, Alabama. Dr. Burnett is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Angiosarcoma of the Scalp, Vaginal Cancer, and Fibrosarcoma. Dr. Burnett is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fiveash's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile